By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Roche today announced agreements to develop a diagnostic assay for the detection of epidermal growth-factor receptor mutations and a PCR-based companion diagnostic test to identify patients with non-small cell lung cancer with EGFR-activating mutations.

In separate agreements, Roche has obtained a worldwide sub-license from Genzyme to develop the EGFR assay, and will collaborate with OSI Pharmaceuticals to develop the companion diagnostic.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.